Development of a pediatric liver CEUS criterion to classify benign and malignant liver lesions in pediatric patients: a pilot study
- 5 March 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in European Radiology
- Vol. 31 (9), 6747-6757
- https://doi.org/10.1007/s00330-021-07784-2
Abstract
Objectives To analyze the contrast-enhanced ultrasound (CEUS) characteristics of pediatric patients with focal liver lesions (FLLs) and develop a pediatric liver CEUS criterion to improve the diagnostic performance of CEUS in differentiating pediatric benign and malignant liver lesions. Methods Between March 2011 and May 2020, patients < 18 years who underwent CEUS were retrospectively evaluated. The CEUS characteristics of FLLs were analyzed. A pediatric liver CEUS criterion categorized as CEUS-1 to CEUS-5 was developed. The diagnostic performance of the criterion (i.e., sensitivity, specificity, PPV, and NPV) was assessed. Chi-square and Mann-Whitney tests were used. Results After exclusion, the study included 130 lesions (mean diameter, 7.1 cm; range, 0.8–17.0 cm) from 130 patients (mean age, 36.0 months; range, 0.03–204.0 months; 74 boys). Hyperenhancement with washout in patients < 5 years or with early washout (≤ 45 s) was used to predict hepatoblastoma, with a sensitivity and specificity of 90.7% (95% confidence interval [CI]: 77.9%, 97.4%) and 93.6% (95% CI: 84.3%, 98.2%), respectively. Peripheral discontinuous globular hyperenhancement was used to diagnose hemangioma, with a sensitivity and specificity of 84.6% (95% CI: 65.1%, 95.6%) and 100% (95% CI: 95.4%, 100.0%), respectively. The rates of malignancies within the pediatric liver CEUS-1, CEUS-2, CEUS-3, CEUS-4, and CEUS-5 categories were 0.0%, 0.0%, 5.6%, 50.0%, and 96.1%, respectively. Besides, the incidences of hepatoblastoma in pediatric liver CEUS-3, CEUS-4, and CEUS-5 were 5.6%, 16.7%, and 67.5%, respectively. Conclusions The pediatric liver CEUS criterion is useful in differentiating benign focal liver lesions from malignancies, especially hepatoblastoma from hemangioma. Key Points • Hyperenhancement with washout in patients • Peripheral discontinuous globular hyperenhancement was used to diagnose hemangioma, with a sensitivity and specificity of 84.6% and 100.0%. • The rates of malignancies within the pediatric liver CEUS-1, CEUS -2, CEUS-3, CEUS-4, and CEUS-5 categories were 0.0%, 0.0%, 5.6%, 50.0%, and 96.1%, respectively.Keywords
Funding Information
- Guangdong Basic and Applied Basic Research Foundation (2019A1515010549)
- National Natural Science Foundation of China (81501480)
This publication has 24 references indexed in Scilit:
- The value of clinical and ultrasound features for the diagnosis of infantile hepatic hemangioma: Comparison with contrast-enhanced CT/MRIClinical Imaging, 2018
- Pediatric Liver TumorsClinics in Liver Disease, 2018
- Safety of Intravenous Application of Second-Generation Ultrasound Contrast Agent in Children: Prospective AnalysisJapanese Journal of Clinical Oncology, 2015
- Infantile Hepatic Hemangioendothelioma in Comparison with Hepatoblastoma in Children: Clinical and Ultrasound FeaturesHepatitis Monthly, 2013
- Safety of contrast-enhanced ultrasound in children for non-cardiac applications: a review by the Society for Pediatric Radiology (SPR) and the International Contrast Ultrasound Society (ICUS)Pediatric Radiology, 2013
- From the Archives of the AFIP: Pediatric Liver Masses: Radiologic-Pathologic Correlation Part 2. Malignant TumorsRadioGraphics, 2011
- CT and MR imaging characteristics of infantile hepatic hemangioendotheliomaEuropean Journal of Radiology, 2010
- Pediatric Liver Masses: Radiologic-Pathologic Correlation Part 1. Benign TumorsRadioGraphics, 2010
- Liver tumors: Pediatric populationLiver Transplantation, 2008
- Epidemiology of primary hepatic malignancies in U.S. childrenHepatology, 2003